Thomas Tibbitts, based in Cambridge, MA, US, is currently a Chief Executive Officer at Dogodan Therapeutics, Inc. (DTI), bringing experience from previous roles at New Terrapin, LLC, Goldfinch Bio and Third Rock Ventures. Thomas Tibbitts holds a Ph. D. in Biophysics, Structural Biology, X-ray Diffraction @ Brandeis University. With a robust skill set that includes Drug Discovery, Molecular Modeling, Computational Chemistry, Homology Modeling, Structural Biology and more, Thomas Tibbitts contributes valuable insights to the industry. Thomas Tibbitts has 2 emails and 1 mobile phone number on RocketReach.